Posted: 4/18/2022

NCI-Frederick Tissue Source -- Support of the Cancer Genome Atlas Program (TCGA)

The Cancer Genome Atlas (TCGA) is a comprehensive and coordinated effort to accelerate our understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing.
The National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) completed a 3-year TCGA pilot project running from 2006 to 2009. This project was designed to assess the feasibility of a full-scale effort to systematically explore the entire spectrum of genomic changes involved in human cancer. Specifically, the project assessed the technical feasibility and clinical relevance of conducting a comprehensive analysis, including characterization of DNA copy number changes, large (on the order of chromosome segments) and small (1,000-100,000 kb) scale rearrangements, transcription profiling, epigenetic modifications, and sequence variation. The suite of analysis platforms were applied to a common set of molecular analytes obtained from clinically annotated high-quality tumor biospecimens and normal tissue (control). The overarching goals of TCGA are to improve the ability to diagnose, treat, and prevent cancer.

Acceptance of proposals began on Friday, January 13, 2012. Proposals for this solicitation are still being accepted and shall be delivered as requested in the RFP Document’s proposal instructions. Proposals shall continue to be accepted on a rolling basis until the solicitation is amended and closed.
Areas of Interest
The potential BOA holder shall provide documentation of availability of qualified personnel, materials, equipment, facilities not otherwise provided under the terms of this subcontract, as needed to provide annotated biospecimens that will be retrospectively and prospectively procured for The Cancer Genome Atlas. The cancer types include but are not limited to:

Acute Myeloid Leukemia , Invasive Bladder Urothelial Carcinoma, Breast Invasive/Lobular Carcinoma, Cervical Adeno and Squamous Cancer, Uterine Corpus Endometrial (grade 3 and serous), Uterine Corpus Endometrial Carcinoma (higher grade 3 and serous), Esophageal Adeno and Squamous Cancer, Hepatocellular Carcinoma, Cutaneous Melanoma of the Skin (Incl. metastatic), Sarcoma – Dedifferentiated Liposarcoma, Leiomyosarcoma (Uterine and Extremity), Undifferentiated Pleiomorphic Sarcoma, Thyroid Papillary Carcinoma, Diffuse Large B-Cell Lymphoma, Stomach Adenocarcinoma (Diffuse and Intestinal), Head and Neck Squamous, Lower Grade Gliomas (Grades II and III), Lung Adenocarcinoma, Lung Squamous, Kidney/Renal Papillary Carcinoma, Pancreatic Adenocarcinoma and Prostate Adenocarcinoma.

These are the primary tumor specimens sought, although other types may be added at the direction of NCI. A major requirement for this TCGA project is the acquisition of high-quality, clinically annotated primary, untreated tumor specimens from patients with these cancer types. There is also enhanced interest in obtaining specimens from underserved populations. If time and resources permits additional tissue types will be collected and utilized in the project.
Funding Type
Sponsor: Rolling